Published in Osteoporos Int on January 01, 2000
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ (2002) 0.98
Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J (2010) 0.81
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int (2005) 0.81
Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring. Osteoporos Int (2006) 0.80
Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol (1988) 35.68
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
The current and future market for veterinarians and veterinary medical services in the United States. J Am Vet Med Assoc (1999) 9.90
Finding protein similarities with nucleotide sequence databases. Methods Enzymol (1990) 6.63
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med (1997) 4.18
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Engl J Med (1998) 3.29
The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem (1996) 3.26
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J (2006) 3.09
Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology (1992) 3.05
Five-year results of the peer assessment program of the College of Physicians and Surgeons of Ontario. CMAJ (1990) 3.03
Correlates of certification in family medicine in the billing patterns of Ontario general practitioners. CMAJ (1989) 2.91
The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med (1990) 2.89
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol (1997) 2.76
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA (2001) 2.70
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int (2001) 2.67
Fibromyalgia: can one distinguish it from simulation? An observer-blind controlled study. J Rheumatol (2000) 2.64
Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens. J Clin Microbiol (2001) 2.59
Users' guide to evidence-based surgery: how to use an article evaluating surgical interventions. Evidence-Based Surgery Working Group. Can J Surg (2001) 2.55
The development and application of indices of health: general methods and a summary of results. Am J Public Health (1977) 2.53
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol (1990) 2.50
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Blood glucose measurements during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med (1989) 2.45
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
Does strengthening the abdominal muscles prevent low back pain--a randomized controlled trial. J Rheumatol (1999) 2.35
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Agreement among reviewers of review articles. J Clin Epidemiol (1991) 2.25
Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature (1985) 2.15
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage (2002) 2.14
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res (1998) 2.12
Selective inactivation of the transacylase components of the 2-oxo acid dehydrogenase multienzyme complexes of Escherichia coli. Biochem J (1976) 2.10
Female and Male Physicians: Different Practice Profiles: Will increasing numbers of female GPs affect practice patterns of the future? Can Fam Physician (1991) 2.05
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Abnormalities identified in the knees of asymptomatic volunteers using peripheral magnetic resonance imaging. Osteoarthritis Cartilage (2005) 1.98
Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ (1996) 1.97
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage (2002) 1.89
A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res (1980) 1.89
Comparison of cervical, urethral, and urine specimens for the detection of Chlamydia trachomatis in women. J Infect Dis (1991) 1.87
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The osteoporosis care gap in Canada. BMC Musculoskelet Disord (2004) 1.81
Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum (1993) 1.80
Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J (2008) 1.80
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev (2004) 1.74
Use of the standard error as a reliability index of interest: an applied example using elbow flexor strength data. Phys Ther (1997) 1.71
A randomized clinical trial of exercise and spinal manipulation for patients with chronic neck pain. Spine (Phila Pa 1976) (2001) 1.70
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69
Gender differences in practice patterns of Ontario family physicians (McMaster medical graduates). J Am Med Womens Assoc (1991) 1.64
Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med (2001) 1.64
The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int (2007) 1.64
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc (1999) 1.58
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J (1988) 1.57
Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum (1989) 1.55
Oligoribonucleotide synthesis from nucleoside 2'-O-benzyl ethers. Tetrahedron Lett (1966) 1.54
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium. Mutat Res (1976) 1.51
Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Regul Toxicol Pharmacol (1998) 1.51
Acupuncture for neck disorders. Cochrane Database Syst Rev (2006) 1.50
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol (1991) 1.47
Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A (1986) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature (1982) 1.45
Prior score availability: observations using the WOMAC osteoarthritis index. Br J Rheumatol (1991) 1.43
Osteoporosis knowledge and information needs in healthcare professionals caring for patients with fragility fractures. Orthop Nurs (2007) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Br J Obstet Gynaecol (1997) 1.42